文献速递临床试验与 GCP

比较增强版接纳与承诺疗法联合常规善后护理与仅常规善后护理的实用性随机对照试验:癌症生存者康复评估(SURECAN)试验的统计分析计划

Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial.
PubMed 文献 · Trials · 2025-01-30

SURECAN试验评估基于接纳与承诺疗法的个体化干预(ACT+)对已完成根治性癌症治疗但生活质量差的患者的效果与成本效果。该多中心、实用性、两臂、部分聚类随机对照优效性试验目标样本量344例(每臂172例),1:1中央随机。主要结局为52周时癌症治疗功能评估量表-通用版(FACT-G)总分。

要点

  • SURECAN试验比较ACT+联合常规护理与仅常规护理,目标样本量344例(每臂172例)。
  • 主要结局为52周时FACT-G总分,采用部分嵌套混合效应模型分析。
  • 次要结局包括16周和52周时FACT-G子量表、癌症复发恐惧量表、癌症影响量表、医院焦虑抑郁量表、Chalder疲劳量表及身体活动。

核心结论

  • 本文为SURECAN试验的统计分析计划,用于评估ACT+在改善随机化后1年生活质量方面的效果与成本效果;任何探索性或事后分析将在相应分析报告中标明。

研究设计与样本

  • SURECAN为多中心、实用性、两臂、部分聚类随机对照优效性试验,比较ACT+联合常规护理与仅常规善后护理。
  • 目标样本量344例(每臂172例),按1:1比例中央随机。

主要发现

  • 主要结局为52周时FACT-G总分,采用部分嵌套混合效应模型分析,误差项允许异方差。
  • 次要结局包括16周和52周时FACT-G子量表、癌症复发恐惧量表(FCR4)、癌症影响量表正负分量表(IOCv2)、医院焦虑抑郁量表(HADS)、Chalder疲劳量表(CFQ)及基于改良Godin量表的身体活动。
  • 卫生经济学分析将确定52周时基于EQ-5D-5L衍生的质量调整生命年(QALYs)的增量成本效果比(ICER),与常规护理比较。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality of life. We present the statistical analysis plan for assessing the effectiveness and cost-effectiveness of the intervention in improving quality of life 1 year post randomisation. METHODS AND DESIGN: SURECAN is a multi-centre, pragmatic, two-arm, partially clustered randomised controlled superiority trial comparing the effectiveness of ACT + added to usual care with usual aftercare. The target sample size is 344 (172 per arm), randomised centrally in a 1:1 ratio. RESULTS: The primary outcome is the total score of the Functional Assessment of Cancer Therapy scale-General (FACT-G) at 52 weeks, analysed using a partially nested mixed-effects model with heteroskedastic error terms. Secondary outcomes include scores at 16 and 52 weeks: FACT-G subscales; Fear of Cancer Recurrence Inventory (FCR4); positive and negative Impact of Cancer scales (IOCv2); Hospital Anxiety and Depression scale (HADS); Chalder Fatigue Scale (CFQ); and physical activity, measured on a modified version of the Godin scale. Health economic analyses will determine the incremental cost-effectiveness ratio (ICER) in terms of quality-adjusted life years (QALYs) derived from the Euroqol 5-Dimension 5-Level (EQ-5D-5L) compared to usual care at 52 weeks. DISCUSSION: This manuscript is the statistical analysis plan (SAP) and economic evaluation for the SURECAN trial. Any exploratory or post hoc analyses will be identified as such in the respective analysis report. TRIAL REGISTRATION: The trial was prospectively registered. ISRCTN: ISRCTN67900293. Registered on 09 December 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Robinson C, Chalder T, McCrone P, et al. Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial. Trials. 2025. PMID: 39881331. doi:10.1186/s13063-025-08734-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。